Last reviewed · How we verify

Montelukast + Levocetirizine

Hanmi Pharmaceutical Company Limited · Phase 3 active Small molecule

Montelukast + Levocetirizine is a Leukotriene receptor antagonist + Selective H1-receptor antagonist Small molecule drug developed by Hanmi Pharmaceutical Company Limited. It is currently in Phase 3 development for Allergic rhinitis, Asthma (allergic component), Allergic conditions with combined leukotriene and histamine involvement. Also known as: Singulair Tablet, Xyzal Tablet.

This combination blocks cysteinyl leukotriene receptors (montelukast) and histamine H1 receptors (levocetirizine) to reduce allergic inflammation and symptoms.

This combination blocks cysteinyl leukotriene receptors (montelukast) and histamine H1 receptors (levocetirizine) to reduce allergic inflammation and symptoms. Used for Allergic rhinitis, Asthma (allergic component), Allergic conditions with combined leukotriene and histamine involvement.

At a glance

Generic nameMontelukast + Levocetirizine
Also known asSingulair Tablet, Xyzal Tablet
SponsorHanmi Pharmaceutical Company Limited
Drug classLeukotriene receptor antagonist + Selective H1-receptor antagonist
TargetCysLT1 receptor (montelukast); H1 histamine receptor (levocetirizine)
ModalitySmall molecule
Therapeutic areaImmunology / Allergy
PhasePhase 3

Mechanism of action

Montelukast is a selective cysteinyl leukotriene receptor antagonist that inhibits the inflammatory cascade triggered by leukotrienes, which are potent mediators of allergic and asthmatic responses. Levocetirizine is a selective H1-receptor antagonist that blocks histamine-mediated allergic symptoms. Together, they provide dual anti-inflammatory and antihistamine activity for allergic conditions.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Montelukast + Levocetirizine

What is Montelukast + Levocetirizine?

Montelukast + Levocetirizine is a Leukotriene receptor antagonist + Selective H1-receptor antagonist drug developed by Hanmi Pharmaceutical Company Limited, indicated for Allergic rhinitis, Asthma (allergic component), Allergic conditions with combined leukotriene and histamine involvement.

How does Montelukast + Levocetirizine work?

This combination blocks cysteinyl leukotriene receptors (montelukast) and histamine H1 receptors (levocetirizine) to reduce allergic inflammation and symptoms.

What is Montelukast + Levocetirizine used for?

Montelukast + Levocetirizine is indicated for Allergic rhinitis, Asthma (allergic component), Allergic conditions with combined leukotriene and histamine involvement.

Who makes Montelukast + Levocetirizine?

Montelukast + Levocetirizine is developed by Hanmi Pharmaceutical Company Limited (see full Hanmi Pharmaceutical Company Limited pipeline at /company/hanmi-pharmaceutical-company-limited).

Is Montelukast + Levocetirizine also known as anything else?

Montelukast + Levocetirizine is also known as Singulair Tablet, Xyzal Tablet.

What drug class is Montelukast + Levocetirizine in?

Montelukast + Levocetirizine belongs to the Leukotriene receptor antagonist + Selective H1-receptor antagonist class. See all Leukotriene receptor antagonist + Selective H1-receptor antagonist drugs at /class/leukotriene-receptor-antagonist-selective-h1-receptor-antagonist.

What development phase is Montelukast + Levocetirizine in?

Montelukast + Levocetirizine is in Phase 3.

What are the side effects of Montelukast + Levocetirizine?

Common side effects of Montelukast + Levocetirizine include Headache, Somnolence, Pharyngitis, Abdominal pain, Dizziness.

What does Montelukast + Levocetirizine target?

Montelukast + Levocetirizine targets CysLT1 receptor (montelukast); H1 histamine receptor (levocetirizine) and is a Leukotriene receptor antagonist + Selective H1-receptor antagonist.

Related